首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >Analysis of the Expression of Surface Receptors on NK Cells and NKG2D on Immunocytes in Peripheral Blood of Patients with Nasopharyngeal Carcinoma
【24h】

Analysis of the Expression of Surface Receptors on NK Cells and NKG2D on Immunocytes in Peripheral Blood of Patients with Nasopharyngeal Carcinoma

机译:鼻咽癌患者外周血NK细胞表面受体表达及免疫细胞NKG2D表达分析

获取原文
           

摘要

Background: The aberrant expression of surface receptors on immunocytes may represent potential markers of tumorescape for nasopharyngeal carcinoma (NPC). The aim of this study was to investigate the expression of representativereceptors on natural killer (NK) cells and NK group 2, member D (NKG2D) on immunocytes in the peripheral bloodof patients with NPC. Methods: Patients (n = 64) with NPC prior to initiation of treatment were defined as the studygroup. Healthy volunteers (n = 31) served as the control group. The expression of NK cells and NKT cells; the triggeringreceptors NKp30, NKp44, and NKp46 on NK cells; the activating receptor NKG2D on NK cells, CD4+ T cells, andCD8+ T cells; and the inhibitory receptors CD158b and CD159a on NK cells were analyzed by flow cytometry in thetwo groups. Results: Here, our study showed that no differences were observed in terms of the numbers of NK cells orNKT cells, or the expression of CD158b and CD159a on the surface of NK cells between the two groups. Nevertheless,the expression levels of NKp30 and NKp46 on NK cells in the NPC patients were significantly lower than in the healthyindividuals (P < 0.05). No differences existed in the expression of NKG2D on NK cells, but NKG2D on CD8+ T cellsshowed a markedly lower expression in the study group (P < 0.001). Conclusions: Our findings may reflect a possiblemechanism of immune evasion for NPC. The enhancement of immunotherapy concerning NKp30, NKp46, and NKG2Dmay be an innovative treatment strategy for patients with NPC.
机译:背景:免疫细胞表面受体的异常表达可能代表了鼻咽癌(NPC)肿瘤逃逸的潜在标志。这项研究的目的是调查在NPC患者外周血中自然杀伤(NK)细胞和NK组2成员D(NKG2D)上代表性免疫受体的表达。方法:将开始治疗前的NPC患者(n = 64)定义为研究组。健康志愿者(n = 31)作为对照组。 NK细胞和NKT细胞的表达; NK细胞上的触发受体NKp30,NKp44和NKp46; NK细胞,CD4 + T细胞和CD8 + T细胞上的激活受体NKG2D;并通过流式细胞术分析了两组中NK细胞的抑制性受体CD158b和CD159a。结果:在这里,我们的研究表明,两组之间在NK细胞或NKT细胞的数量,或在NK细胞表面上CD158b和CD159a的表达方面均没有差异。然而,NPC患者NK细胞上NKp30和NKp46的表达水平明显低于健康人(P <0.05)。研究组中NKG2D在NK细胞上的表达没有差异,但CD8 + T细胞上NKG2D的表达明显降低(P <0.001)。结论:我们的发现可能反映了鼻咽癌免疫逃逸的可能机制。有关NKp30,NKp46和NKG2D的免疫疗法的增强可能是NPC患者的一种创新治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号